Healthcare Providers

Interested in your institution being a part of this historical trial?

Any institution within the National Cancer Institute’s National Clinical Trials Network (NCTN) may open the Lung-MAP study at their site. Learn more about the protocol at clinicaltrials.gov or by contacting the Lung-MAP protocol coordinators:

Jennifer Beeler, M.A.
Lung-MAP Senior Protocol Project Manager
SWOG Cancer Research Network
Network Operations Center
4201 Medical Drive #250, San Antonio, TX 78229
210.614.8808, Ext 1026 | jbeeler@swog.org

Gabe Chadwell
Lung-MAP Protocol Project Manager
SWOG Cancer Research Network
Network Operations Center
4201 Medical Drive #250, San Antonio, TX 78229
210.614.8808, Ext 1952 | gchadwell@swog.org

What are the latest developments with Lung-MAP?

As it starts its second decade, Lung-MAP has undergone another major update – referred to as Lung-MAP 3.0 – greatly broadening access to the trial by expanding the list of next-generation sequencing (NGS) tests that can be used in enrolling patients. We made this update because NGS testing has become a standard part of the treatment process for most patients with non-small cell lung cancer – the update keeps Lung-MAP as patient focused as possible.

Most patients with known genomic profiling results may now use these results to participate in the trial. For patients who do not already have results based on an NGS test that is approved for use in Lung-MAP, the trial continues to provide on-study NGS testing by the FoundationOne companion diagnostic test.

Lung-MAP 3.0 greatly simplifies screening, making clinical trials of new treatments available to even more patients at a wider range of community sites. Allowing the use of more NGS tests means Lung-MAP is even better positioned to enroll a group of patients fully representative of the diverse population of patients with advanced non-small cell lung cancer in the U.S.

How does Lung-MAP evaluate investigational treatments?

Each investigational treatment is evaluated within an independently conducted sub-study of Lung-MAP. Sub-studies fall into two broad categories: biomarker-matched and non-match sub-studies.

Each eligible patient will be assigned in one of two ways to a Lung-MAP sub-study evaluating an investigational treatment. They will either make a genomic “match” to a biomarker-driven sub-study testing an investigational drug for that biomarker-defined population, or they will potentially be eligible for a non-match sub-study that tests an immunotherapy combination.

What are the main objectives of Lung-MAP?

The primary objective of biomarker-matched sub-studies in Lung-MAP is to learn whether targeted cancer therapies matched to the genomic makeup of a patient’s lung cancer tumors are more effective than the current standard therapies in halting or reversing the progress of the disease and in extending the patient’s life.

The primary objective of a non-match sub-study is to learn if treatments combined with immunotherapy are more effective than standard of care for treating lung cancer previously treated with immunotherapy (either alone or in combination with chemotherapy).

What are the benefits of the Lung-MAP approach to cancer research?

• Enrollment efficiency: A single screening process that can match patients at the time of disease progression to multiple trial sub-studies is more efficient than a separate screening process for each trial. The third-generation Lung-MAP screening process can use a patient’s prior tissue test results from the vast majority of CLIA-certified NGS platforms now in use.
• Operational efficiency: All sub-studies are conducted under one IND and IRB and follow a consistent, structured protocol template that lets them be more easily implemented at sites. Furthermore, the NCI counts accruals to all of Lung-MAP and its sub-studies as one study, allowing many sites to open studies in “rare” biomarker-defined populations.
• Predictability: If a drug meets predetermined efficacy and safety criteria, the drug and its accompanying diagnostic biomarker will be eligible for FDA approval.

Who is conducting the Lung-MAP trial?

The trial is open at cancer centers, community hospitals, academic medical centers, and physician cooperatives across the United States, with operations being managed by SWOG Cancer Research Network and participation by all adult cancer research groups within the NCI’s NCTN.

Where can I learn more about Lung-MAP?

More detailed information about the trial and its sub-studies can be found in the Members Section of the CTSU website.